文献速递肝病

MicroRNAs在肝病中的调控、生物标志物与治疗靶点作用

MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases.
PubMed 文献 · Gut · 2020-10-30

本文综述了miRNAs在肝病中的调控与功能,重点讨论了肝细胞特异性或富集的miRNA(如miR-122、miR-194/192)、中性粒细胞(miR-223)、肝星状细胞(miR-29)、免疫细胞(miR-155)及循环中的miR-21。这些miRNA在酒精性肝病、非酒精性脂肪性肝病、药物性肝损伤、病毒性肝炎、肝细胞癌、肝纤维化和肝衰竭中发挥重要作用。文章还探讨了miRNA作为早期诊断、预后和评估肝病的生物标志物的应用前景,以及基于miRNA治疗的挑战。

要点

  • miR-122、miR-194/192、miR-223、miR-29、miR-155和miR-21在肝病中表达改变并调控病理过程。
  • miRNA参与酒精性肝病、NAFLD、DILI、病毒性肝炎、HCC、肝纤维化和肝衰竭。
  • miRNA可作为肝病早期诊断、预后和评估的生物标志物,并具治疗潜力。

核心结论

  • miRNAs通过转录后调控基因表达参与肝病发生发展,是潜在的诊断标志物和治疗靶点。

研究设计与样本

  • 综述类文章,检索范围未在摘要中明确说明。

主要发现

  • 肝细胞特异性或富集的miR-122和miR-194/192、中性粒细胞miR-223、肝星状细胞miR-29、免疫细胞miR-155及循环miR-21在肝病中表达改变。
  • 这些miRNA的功能和靶基因在酒精性肝病、非酒精性脂肪性肝病、药物性肝损伤、病毒性肝炎、肝细胞癌、肝纤维化和肝衰竭中受到强调。
  • miRNA通过细胞外囊泡介导肝细胞与其他细胞间的通讯,参与肝病发病机制。

临床怎么用

  • miRNA可作为肝病早期诊断、预后和评估的生物标志物。
  • 基于miRNA的治疗策略在肝病中具有潜力,但面临挑战。

局限性

  • 基于miRNA的治疗在肝病中的应用仍存在挑战。
  • 需要进一步研究miRNAs在肝脏中的作用以理解肝病发病机制并识别生物标志物和治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

MicroRNAs (miRNAs) are small, non-coding RNAs that post-transcriptionally regulate gene expression by binding to specific mRNA targets and promoting their degradation and/or translational inhibition. miRNAs regulate both physiological and pathological liver functions. Altered expression of miRNAs is associated with liver metabolism dysregulation, liver injury, liver fibrosis and tumour development, making miRNAs attractive therapeutic strategies for the diagnosis and treatment of liver diseases. Here, we review recent advances regarding the regulation and function of miRNAs in liver diseases with a major focus on miRNAs that are specifically expressed or enriched in hepatocytes (miR-122, miR-194/192), neutrophils (miR-223), hepatic stellate cells (miR-29), immune cells (miR-155) and in circulation (miR-21). The functions and target genes of these miRNAs are emphasised in alcohol-associated liver disease, non-alcoholic fatty liver disease, drug-induced liver injury, viral hepatitis and hepatocellular carcinoma, as well liver fibrosis and liver failure. We touch on the roles of miRNAs in intercellular communication between hepatocytes and other types of cells via extracellular vesicles in the pathogenesis of liver diseases. We provide perspective on the application of miRNAs as biomarkers for early diagnosis, prognosis and assessment of liver diseases and discuss the challenges in miRNA-based therapy for liver diseases. Further investigation of miRNAs in the liver will help us better understand the pathogeneses of liver diseases and may identify biomarkers and therapeutic targets for liver diseases in the future.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Wang X, He Y, Mackowiak B, et al. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut. 2020. PMID: 33127832. doi:10.1136/gutjnl-2020-322526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。